DEENOVA
17.5.2022 06:02:07 CEST | Business Wire | Press release
Deenova today announced that it continued its last 2 years market dominance in France with another net new RESAH competitive award for its D3 ACCED mechatronic solutions at Centre Hospitalier Hazebrouck near Dunkerque. Separately, Deenova is pleased to simultaneously announce add-on sales of 4 ASTUS cabinets to existing Deenova customer Centre Hospitalier François Quesnay de Mantes-La-Jolie .
Loïc Bessin , Managing Director of Deenova in France stated: “Combining net new business awards at premier hospital groups like RESAH with Centre Hospitalier Hazebrouck , while at the same time earning the trust of additional add-on sales by previous Deenova customers such as Centre Hospitalier François Quesnay de Mantes-La-Jolie is self-evident proof of Deenova France maturity, showing a high level of continued satisfaction with our automation solutions amongst our existing customer base in France.”
Christophe Jaffuel , Deenova Chief Commercial Officer, added: “I am extremely pleased to continue to witness since 2019 the important and yearly contribution that RESAH ongoing awards means to Deenova in France, renewing its past commitment to Deenova well established mechatronic Unit-Dose solutions like D3 ACCED . I look forward to continuing the market leading cooperation with RESAH in the future.”
Centre Hospitalier Hazebrouck is a public health establishment located in the Lille Métropole healthcare area, and certified by the High Authority for Health in 2019. It assumes the functions of a local hospital for a population of approximately 124,000 inhabitants, with a capacity of 94 hospital beds, centered on medicine, surgery and gynecology-obstetrics, an Emergency Reception Service and a Home Hospitalization service. It also has an accommodation structure for the elderly (EHPAD) with 136 beds, a CSAPA (Centre for Care, Support and Prevention in Addictology) and 20 Aftercare and Rehabilitation beds. Patients benefit from consultations and expert advice as well as a high-quality technical platform with a medical imaging, 4 operating theaters, 3 birthing rooms, a pharmacy and sterilization units with 470 medical and non-medical staff.
Centre Hospitalier François Quesnay de Mantes-La-Jolie is a public health establishment opened in October 1997, bringing together all short-stay services (medicine, surgery, obstetrics), Aftercare and Rehabilitation (SSR), with 612-bed hospital in the Paris metropolitan area, and with a budget of 125 million euros and 175 doctors.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005991/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 22:42:00 CEST | Press release
New Tickets, Exclusive Offers, and Special Anniversary Programs Kick off May 1 The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 22:17:00 CEST | Press release
Recognizes the potential of MH002 to address a serious medical condition with high unmet need Enables accelerated development and increased FDA interactions to streamline review process MRM Health will be presenting at upcoming Digestive Disease Week (DDW) 2026, taking place from May 2nd – May 5th in Chicago, IL, USA MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process d
Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results30.4.2026 22:01:00 CEST | Press release
First Quarter Financial Highlights Include: Remaining Performance Obligations (RPO) of $643.6 million, up 16.4% year over year Adjusted Calculated Billings of $92.2 million, up 22.9% year over year Adjusted Annualized Recurring Revenue (ARR) of $388.0 million, up 5.0% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430598629/en/ Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results “Our first quarter results reflect continued growth and accelerating momentum in our core Rimini Support™ business as organizations turn to the proven Rimini Smart Path™ to execute their global E
OpenAI and Yubico Partner to Bring Custom Phishing-Resistant YubiKeys to OpenAI Users30.4.2026 19:13:00 CEST | Press release
New strategic, long-term partnership with OpenAI delivers the gold standard of hardware-backed passkeys to the AI ecosystem Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the YubiKey, the gold standard of security keys, today announced an industry-first collaboration with OpenAI, the creator of ChatGPT. Beginning today, people can purchase a new 2-pack set of custom YubiKeys as part of OpenAI’s Advanced Account Security program – enabling them to secure their ChatGPT accounts with security keys, containing the strongest hardware-backed passkeys. Specifically designed for security-conscious users who are at increased risk of targeted digital attacks, the set includes a YubiKey C NFC for tap-to-authenticate on mobile, and a low profile YubiKey C Nano that stays in a port for everyday laptop use – both packed with modern authentication features for the highest level of protection. With OpenAI already using YubiKeys internally to protect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom